May 30

Pharmaphorum Podcast: Move over CAR-T – the Potential of NK Cells in Cell Therapy

[excerpt] The early successors in cell therapy have mostly been CAR-T therapies, with the T standing for T cells. But T cells aren’t the only option for cell therapy. Promising work is being done with natural killer, or NK cells, a different kind of immune system cell that could work even better in some ways.

On this pharmaphorum podcast, Dr. Fred Aslan, Artiva’s CEO talks with host Jonah Comstock about the potential of NK cells as an allogeneic cell therapy approach in autoimmune disease and the importance of a robust manufacturing process.

Find episode 126 (dated May 30, 2024) on iTunes, Spotify, and Stitcher or on pharmaphorum’s website, which has a podcast player or the option to download the episode.

Recent Posts

See All

The Bio Report Podcast: Turning Natural Killers into Off-the-Shelf Therapies for Autoimmune Disease

NK cells, part of the innate immune system, serve as the body’s first line of defense. These cells can recognize and kill abnormal or infected cells. As therapies, they have the advantage over CAR-T and other cell therapies because they can be used off-the-shelf without undergoing gene editing or other genetic modifications. They also don’t...

In Vivo: Artiva Leverages Unmodified NK Cells To Challenge CAR-T Paradigm

Artiva’s President and CEO Fred Aslan, M.D., explores how Artiva is reshaping cell therapy with In Vivo.  In the maturing landscape of cell therapy, Artiva Biotherapeutics stands out for its unique approach: using un-engineered natural killer (NK) cells for oncologic and immune indications. Read the full article here (subscription may be required).

Drug Discovery World: Expanding Access to Cell Therapies for Autoimmune Conditions

DDW Editor Reece Armstrong speaks to Fred Aslan, MD, President and Chief Executive Officer of Artiva Biotherapeutics, about how to scale-up access to cell and gene therapies for patients suffering from autoimmune diseases. The rise of cell therapies in the past decade has led to meaningful clinical responses across both haematological diseases like blood cancer,...